This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Discovery Corporation Agrees With The U.S. Preventive Services Task Force’s Position Against PSA-Based Screening For Prostate Cancer And Believes Its Four-Gene Assay For Prostate Cancer Is The Best Alternative To PSA

Health Discovery Corporation (OTCBB: HDVY) today announced its agreement with the U.S. Preventive Services Task Force’s (USPSTF) stance against the use of the prostate-specific antigen (PSA), a test used by 90 percent of U.S. men to screen for prostate cancer. In a draft recommendation released Friday, the Task Force sided against the PSA test, stating that patients are substantially more likely to be harmed by the adverse effects of aggressive treatment prompted by ambiguous test results than they are to reap benefits such as better health or longer life. HDC agrees with reported results that a patient’s quality of life may suffer from overtreatment caused by anxiety, urinary incontinence, erectile dysfunction, impotence, coronary heart decease, diabetes, increased breast size and hot flashes, depending on treatment. HDC adds that diminished reliance on PSA testing will also help reduce cases of infection and/or nerve damage that have been reported by some patients following biopsy procedures. However, HDC supports prostate cancer screening with a more reliable prostate cancer test and believes that such screening will save lives.

"In a recent clinical trial, HDC’s urine based four-gene prostate cancer test successfully outperformed serum PSA," stated Dr. Herbert Fritsche, Chief Science Officer, Health Discovery Corporation and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. "The HDC urine-based four gene prostate cancer test was shown to identify 90% of cancers while eliminating 50% of unnecessary biopsies and therefore significantly reducing potentially unnecessary treatments including surgeries that would otherwise have been performed."

Further explaining the advanced development of HDC’s urine-based prostate cancer test, Stephen D. Barnhill, M.D., Chairman and CEO, Health Discovery Corporation, notes that, "We have now demonstrated to our satisfaction that the 4-gene urine test for clinically significant prostate cancer outperformed serum PSA and Digital Rectal Exam (DRE), as well as published data for PCA3 and TMPRSS-ERG assays for the early detection of prostate cancer.” Furthermore, additional studies are planned to explore the potential of the 4-gene test to distinguish patients with aggressive disease that require aggressive therapy from those who have a more benign cancer and do not need aggressive treatment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs